




## NARRATIVE REVIEW

# Rift valley fever (RVF) viral zoonotic disease steadily circulates in the Mauritanian animals and humans: A narrative review

Ranjan K. Mohapatra<sup>1</sup>  | Lakshmi V. S. Kutikuppala<sup>2</sup> | Venkataramana Kandi<sup>3</sup> | Snehasish Mishra<sup>4</sup> | Ali A. Rabaan<sup>5,6,7</sup> | Sharo Costa<sup>8</sup> | Zahraa Haleem Al-qaim<sup>9</sup> | Bijaya K. Padhi<sup>10</sup>  | Ranjit Sah<sup>11,12,13</sup> 

<sup>1</sup>Department of Chemistry, Government College of Engineering, Keonjhar, Odisha, India

<sup>2</sup>Department of General Surgery, Dr. NTR University of Health Sciences, Vijayawada, Andhra Pradesh, India

<sup>3</sup>Department of Microbiology, Prathima Institute of Medical Sciences, Karimnagar, Telangana, India

<sup>4</sup>School of Biotechnology, Campus-11, KIIT Deemed-to-be-University, Bhubaneswar, Odisha, India

<sup>5</sup>Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia

<sup>6</sup>College of Medicine, Alfaisal University, Riyadh, Saudi Arabia

<sup>7</sup>Department of Public Health and Nutrition, The University of Haripur, Haripur, Pakistan

<sup>8</sup>College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan, USA

<sup>9</sup>Department of Anaesthesia techniques, Al-Mustaqbal University College, Hilla, Babylon, Iraq

<sup>10</sup>Department of Community Medicine, School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, India

<sup>11</sup>Institute of Medicine, Tribhuvan University Teaching Hospital, Kathmandu, Nepal

<sup>12</sup>Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth, Pune, Maharashtra, India

<sup>13</sup>Department of Public Health Dentistry, Dr. D. Y. Patil Dental College and Hospital, Dr. D. Y. Patil Vidyapeeth, Pune, Maharashtra, India

## Correspondence

Ranjit Sah, Institute of Medicine, Tribhuvan University Teaching Hospital, Kathmandu, Nepal.

Email: [ranjitsah57@gmail.com](mailto:ranjitsah57@gmail.com)

## Abstract

**Background and Aim:** Rift valley fever (RVF) virus (RVFV) is reportedly steadily circulating in Mauritania being reported in 1987, 2010, 2012, 2015, and 2020. Mauritania seems a preferred niche for RVF virus due to its persistent outbreak there. Lately, nine Mauritanian wilayas confirmed 47 (23 fatalities with 49% CFR) human cases between August 30 and October 17, 2022. Most of the cases were largely among livestock breeders associated with animal husbandry activities. The review aimed at understanding the origin, cause, and measures to counter the virus.

**Methods:** The facts and figures from the various published articles sourced from databases including Pubmed, Web of Science, and the Scopus as also some primary data from health agencies like WHO, CDC, and so forth were evaluated and the efficacy of countermeasures reviewed.

**Results:** Among the reported confirmed cases, it was found that 3–70 year age-group males outnumbered the females. Deaths after fever occurred primarily due to acute hemorrhagic thrombocytopenia. Human infections often occurred through zoonotic transmission mainly through mosquitoes in the population contiguous to

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2023 The Authors. *Health Science Reports* published by Wiley Periodicals LLC.

cattle outbreak, a conducive site for local RVFV transmission. Many transmission cases were through direct or indirect contact with blood or organs of the infected animal.

**Conclusion:** RVFV infection was predominant in the Mauritanian regions bordering Mali, Senegal, and Algeria. High human and domesticated animal density as also the existing zoonotic vectors further contributed to RVF virus circulation. Mauritanian RVF infection data confirmed that RVFV was zoonotic that included small ruminants, cattle, and camel. This observation hints at the role of transborder animal mobility in RVFV transmission. In light of this, preventive approaches with effective surveillance and monitoring system following the One Health model is extremely beneficial for a free and fair healthy world for all.

#### KEYWORDS

diagnosis and complications, epidemiology, etiological agent, Mitigation strategy, public health response, Rift valley fever (RVF)

## 1 | INTRODUCTION

The first Rift valley fever (RVF) outbreak was reported from the Rift valley in 1915, hence the name. The RVF virus was then first isolated from a sheep in a Kenyan farm in 1931.<sup>1</sup> Since then, owing to the trade of infected livestock, and high rainfall with extensive flooding sporadic RVF outbreaks are being reported in sub-Saharan Africa (Figure 1).<sup>2</sup> Its spread to Saudi Arabia and Yemen in 2000, first reported RVF case outside the African continent, could be attributed to the trading of infected livestock. That it could reach to other places including the Asia and the Europe (<https://www.who.int/news-room/fact-sheets/detail/rift-valley-fever>) is concerning.

Setting in severe illness, the viral zoonosis RVF is typically endemic to sub-Saharan Africa affecting domesticated animals like goat, sheep, cattle, buffalo, and camels, although it potentially could infect humans too. RVF viral disease transmits from infected animals to humans through contact with their body fluids, blood, or tissues or through the bite an infected mosquito. RVF illness causes major economic losses due to deaths and abortions among livestock.<sup>3</sup> RVF virus is circulating steadily in Mauritania with reported epidemics in 1987, 2010, 2012, 2015, and 2020. Between August 30 and October 17, 2022, nine of the 15 Mauritanian wilayas (regions) reported a total of 47 confirmed human RVF cases with 23 fatalities (49% CFR) predominantly among livestock breeders.<sup>4</sup> Males outnumbered the females among the confirmed cases (M:F:4.4:1), the age group ranging between 3 and 70 years with 22 years median age. Almost all the deaths were in hospitals due to hemorrhagic syndrome with symptoms like acute thrombocytopenia and fever (petechiae, hematemesis, gingivorrhagia).<sup>4</sup> RVF contracting virus circulates in small ruminants, camels, and cattle in eight Mauritanian wilayas. Till recently, 12 wilayas in all including the nine that share borders with three nations, Mali, Senegal, and Algeria, have reported confirmed human or animal illnesses. Due to RVF prevalence in most wilayas,


the animal density, and the large human and animal mobility to neighboring nations, the regional spread of the outbreak cannot be ruled out even in the face of the outbreak response being managed through One-Health strategy.<sup>4</sup>

## 2 | THE FIRST REPORTED CASE OF THE PRESENT OUTBREAK

The Mauritania Ministry of Health alerted the WHO of a RVF outbreak on August 30, 2022 after polymerase chain reaction (PCR) test done on a 25-year-old male animal breeder from the Tintane moughataa in the Hodh El Gharbi wilaya at the National Institute for Public Health Research lab confirmed a RVF case on August 29.<sup>4</sup> The patient first showed up at a clinic on August 25 with hemorrhagic (epistaxis) syndrome and acute thrombocytopenia. He was shifted to a nearby hospital the next day where he passed away on August 29.

## 3 | ANIMAL CASES

While nine wilayas have reported RVF cases in human as of October 17, 2022, 12 wilayas have reported eight confirmed and four suspected animal cases. Potential animal RVF cases was alerted from sentinel herd monitoring that notified animal deaths and abortions in Aioun moughataa, Hodh El Gharbi wilaya. RVF outbreak in animals was subsequently identified in Hodh El Gharbi and seven other (Adrar, Assaba, Guidimakha, Hodh Echargui, Tagant, Tiris Zemmour, and Trarza) wilayas. Out of the 1148 samples of animal origin (from cattle, camel, and small ruminants) were analyzed between August 18 and October 10, 2022, positive cases were 277 (24.1%). IgM ELISA in cattle and small ruminants, and RT-PCR tests in camels revealed 5.2% (5/96), 25.9% (159/614), and 25.8% (113/438) positive cases.<sup>4,5</sup>



**FIGURE 1** Distribution map of RVF reported cases in the sub-Saharan Africa (<https://www.cdc.gov/vhf/rvf/outbreaks/distribution-map.html>). The reported cases are high in almost whole of the Southern peninsula while the status in the northern part is ill-reported. RVF, Rift valley fever.

#### 4 | EPIDEMIOLOGY

Typical RVF hosts in the sub-Saharan Africa are domesticated animals like goat, sheep, cattle, buffalo, and camel.<sup>6</sup> Although the disease mostly affects animals, RVF can also infect humans. While mosquito-

bite brings in the disease in humans, the infection could also be by touching the blood or organs of the infected animal.<sup>2</sup> The high-risk occupational groups include farmers, herders, abattoir staff, and veterinarians. Consuming unpasteurized or raw milk from the diseased animals can also transmit the infection in humans. However,

evidence of human–human RVF transmission is not yet reported. Even while RVF frequently results in serious illness in animals, it can manifest as a moderate flu in humans to fatal hemorrhagic fever. Most RVF-infected humans either show no or only moderate symptoms (fever, weakness, back pain, and dizziness).<sup>4</sup> Serious symptoms like encephalitis (swelling of brain), bleeding, and eye damage are experienced by only a tiny proportion (8%–10%) of the RVF patients. Mauritania reported 25 fatalities (CFR 32%) and 78 recorded human infections of the RVF outbreak from September to November 2020. Out of the recorded cases, 94 camels, 89 small ruminants, and 3 cattle were among the 186 RVF-contracted animals.<sup>4</sup>

## 5 | THE ETIOLOGICAL AGENT

RVF virus belongs to family Bunyviridae and genus *Phlebovirus*. It is an RNA virus with segmented (in three segments) ribonucleic acid. RVF is a viral disease primarily of veterinary importance. It infects domesticated and wild animals including lions, elephants, bats, and rodents, and humans too through direct contact with the diseased animals or mosquito bite (*Aedes* sp.).<sup>2,4</sup> Handling infected animals especially in the abattoir and eating contaminated meat could also transmit.<sup>7</sup> Human–human viral transmission is yet to be reported. RVF virus was detected in Eastern African region in 1931 that later spread throughout the African continent. Due to globalization and increased human and animal movements, RVF spreading to other parts of the world has all possibility. In view of its flexible and multiple modes of transmission, the WHO listed it as a potentially emerging microbe that could be a public health emergency to address.<sup>7,8</sup>

RVF virus (RVFV) continues to be a threat due to the fact that it remains in the environment through the transovarial transmission with mosquitoes both as reservoirs and vectors. Other mosquito species (like *Anopheles* and *Culex*) and other insects including sandflies can also transmit.<sup>2</sup> Wild animals have also been noted as reservoirs, and the enzootic life cycle of the virus facilitates its survival.<sup>9</sup> The epizootic life cycle of the virus is active during excess rainfall seasons wherein mosquitoes proliferate extensively. It results in infecting the livestock including domesticated animals like cattle, sheep, goat, as also humans.<sup>10</sup>

## 6 | RVFV DIAGNOSIS AND COMPLICATIONS

RVFV infection in humans is usually self-limiting. However, it may develop into severe conditions including fatal hemorrhage.<sup>11</sup> Its infection may lead to obstetric complications and neonatal infections among pregnant women. Due to the nature of the virus to potentially cause life threatening infections, RVFV can only be handled in a biosafety level-3 laboratory. The unavailability of such infrastructure in the endemic regions could potentially contribute to diagnosis and

transmission complications. As per the WHO, definitive RVF diagnosis in humans could be done through RT-PCR, Loop-mediated isothermal amplification (LAMP), next generation sequencing (NGS), and detection of antigens and antibodies (IgM and IgG) by ELISA of the clinical specimen.<sup>12</sup> Endemic circulation of RVFV was identified in KwaZulu-Natal province, South Africa, evident by the presence of IgG and IGM antibodies in the tested population presenting fever-like symptoms. The most common symptoms among the seropositive individuals included fever, headache, and arthralgia.<sup>13</sup> In a study in Botswana, antibodies were also verified in individuals with no clinical symptoms.<sup>14</sup> In an Ethiopian study, 13.2% seroprevalence was recorded in humans and 62% in camels.<sup>15</sup>

The pandemic potential of RVFV and the unavailability of approved vaccines and therapeutic agents is a matter of serious concern with regard to public health.<sup>16</sup> Coordinated effort between the public and animal health administrations in line with the One Health approach to control the spread sporadic diseases like RVF is suggested. It could be achieved by antibodies and RT-PCR based surveillance programmes to screen and diagnose RVF in humans and domesticated animals.<sup>17–19</sup> Antibodies against viral nucleo- and glycoproteins could facilitate the diagnosis.<sup>20</sup> A low-density lipoprotein receptor-related protein 1 (Lrp1) was identified as a potential receptor for viral glycoprotein attachment and the entry of the virus into the cells. Clustered repeatedly interspaced short palindromic repeats (CRISPR) studies also noted that other host proteins including heat shock protein (Grp94), and receptor-associated protein were critical in RVFV infection.<sup>21</sup> Nonstructural NS protein of RVFV was identified as a potential virulence factor that was neurotoxic and could damage brain cells.<sup>22,23</sup> RVFV infection can cause hepatitis, hemorrhage, and leukopenia in humans, and it could affect different tissues generally resulting in ocular and neurological pathology.<sup>24</sup> The pathophysiology of RVFV infection appears to be complex. Both innate and acquired immunity play a key role in the pathogenesis and disease outcome. RVFV infection commonly led to the necrosis/lesions of the liver, endothelial damage, ascites, pulmonary, and lymph node congestion and edema in humans and animals. Necrosis, hemorrhage, multiorgan failure, and circulatory shock may result in death.<sup>25</sup>

## 7 | PUBLIC HEALTH RESPONSE

The 2018–2019 RVFV human outbreaks in France noted that more than 70% of the infections were related to exposure to blood and body fluids of the infected animals.<sup>26</sup> More than 98% of the human patients infected with RVFV in Sudan revealed that their domesticated animals either died or had suffered from abortion before they had encountered the symptoms. This confirms the ease of animals-to-humans spread of RVFV.<sup>27</sup> Keeping in view previous outbreaks, the epidemic response in Mauritania is being managed using One Health model including creating One Health technical committee to coordinate the response at the national level. Camels might be crucial in local amplification of RVFV in Mauritania.<sup>28</sup> Weekly meetings

between the human health and animal health coordination committees are held in the affected wilayas. In-depth epidemiological and entomological investigations, daily meetings, community sensitization, provision of medications and personal protective equipment, improving the diagnostic and management capabilities of health facilities in the affected areas, and mobilizing the partners for material and financial support are the priorities.<sup>29</sup>

## 8 | RISK ASSESSMENT

Mauritania encountered RVF in 1987, 2010, 2012, 2015, and 2020. Transmission can be during animal slaughter, through contact with tainted blood or tissues, and through the bite of the carrier mosquito.<sup>2,4,29</sup> The illness spreading to humans after the confirmed case of circulation of the virus in animals in various regions throughout the majority of wilayas is highly likely. High animal densities, insufficient sanitation services, and unstable environmental conditions all contribute to the growth of vectors and the transmission of the virus. Copious rainfall this year leading to flood in the majority of these wilayas, dumping of used tyres, used containers and debris have all contributed to increased vector breeding sites.<sup>4</sup>

Although the global risk of RVF is estimated low, but the risk of its spread at regional levels is moderate. Since Mauritania is an agro-pastoral nation, the transmission risk increases owing to the movement of animals in search of pasture and water. Regular pastoral cross-border movements raise the danger of disease being disseminated to neighboring nations.<sup>30</sup> As indicated earlier, nine of the 15 wilayas of Mauritania border Mali, Senegal, and Algeria, and 14 of them have reported confirmed human, confirmed animal, and suspected animal cases.<sup>31</sup> The wilayas of Assaba, Adrar, Hodh El Chargui, Hodh El Gharbi, Guidimakha, and Tiris Zemmour border Mali, and Brakna, Gorgal, Guidimakha, and Trarza border Senegal. The transhumance practise, defined by pastoralism and the movement of livestock under the care of herders, is common in Mauritania and transborder into Mali and Senegal. The risks are further high as RVF is not among the illnesses subject to vaccination control in animals, and some nations in the subregion rely on Mauritanian markets to supply their livestock.<sup>4</sup>

## 9 | MITIGATION STRATEGY

Human infections frequently occur adjacent to cattle outbreaks in a setting that favors local transmission of RVFV by mosquito vectors. Mosquito species like *Culex poicilipes*, *Culex quinquefasciatus*, *Culex antennatus*, *Culex univittatus*, *Mansonia africana*, *Aedes vexans*, and *Mansonia uniformis* reportedly are the RVFV transmission vectors.<sup>29</sup> However, the majority of the infected human cases were allegedly through direct or indirect contact with blood or organs of infected animal.<sup>2,4,29</sup> Due precaution needs to be followed while handling ill human or animal including their fluids and laboratory samples.

Awareness campaigns on risk factors for RVF transmission and the preventative measures like vector management and protection from mosquito bites are crucial to reduce the human infections and fatalities cases.<sup>4</sup>

Prior rigorous animal immunization could stop RVF outbreaks. Vaccination campaign during an epizootic is not advised as it could potentially facilitate pathogenic reassortments. Since animal cases of RVF epizootics occur before human cases, active animal health surveillance system for early warning to the veterinary and human health authorities may be established. Although no human-to-human RVF transmission has been documented, there is a theoretical possibility that the healthcare personnel could contract the virus after contacting with the contaminated blood or tissue of a patient. Thus, specimen-handling healthcare professionals could follow preventive measures before handling a suspected or confirmed RVF case.<sup>5</sup> Based on the currently available information regarding this, the WHO advises against implementing any travel or trade restrictions to Mauritania or other affected regions.

## 10 | VACCINES

Most of the human RVF cases are relatively mild, of short duration and may be self-healing, although general supportive therapy for severe cases is suggested. Recently, an inactivated viral vaccine was developed, licensing and commercialization of which is awaited, and tried to protect domesticated animals and laboratory personnel at high risk of RVF exposure.

The first RVF vaccine was developed as a formalin-inactivated NDBR103 Entebbe strain isolated from mosquito to control RVF in Uganda.<sup>32</sup> Formalin or ethyleneamine inactivated RVF vaccine is prepared for veterinary use. The most widely used and the oldest live attenuated Smithburn vaccine using Ugandan *Eretmapodites* spp. began in 1944.<sup>33</sup> Having several disadvantages, live attenuated vaccines are prohibited in the pregnant and in RVF-free countries. As such, no vaccine is authorized in the European Union for human use. A novel formalin-inactivated vaccine TSI-GSD200 was developed by the US Army's Medical Research Institute of Infectious Diseases (USAMRIID).<sup>3</sup> Another live attenuated one MP-12, capable of producing sufficient antibody titer for protection against RVF, was developed by the USAMRIID for both human and veterinary use. It can potentially benefit pregnant animals protecting the newborn.<sup>34</sup> Other vaccine forms using state-of-the-art technology include that of subunit protein, DNA,<sup>35,36</sup> virus replicon particle,<sup>37</sup> virus-like particle,<sup>38</sup> virus vectored,<sup>39</sup> and genetically modified live vaccines.<sup>40</sup>

## 11 | DISCUSSION

Mauritania has steadily witnessed five RVF epidemics in spates from 1987 till 2020. Nine Mauritanian regions reported infections largely among the livestock breeders<sup>4</sup> allegedly handling goat, sheep, cattle, buffalo, and camel<sup>6</sup> recently, where the males of 3–70 years

age-group outnumbered the females among the confirmed cases. Twelve including the nine wilayas having common borders with Mali, Senegal, and Algeria are affected. Thus, regional spread of the outbreak cannot be ruled out even against the One-Health strategy.<sup>4,41</sup> Global spread of RVF has every possibility due to increased human and animal mobility. All deaths occurred with hemorrhages, acute thrombocytopenia, and fever symptoms.<sup>4</sup> Small ruminants, camels, and cattle are the major known RVF virus carriers. While humans are infected through mosquito bite, contacting blood, or organs of the infected animals could also cause,<sup>2</sup> especially in high-risk occupational groups like farmer, herder, abattoir staff, and veterinarian. *Anopheles* and *Culex* mosquitoes and insects like sandfly could also transmit.<sup>2</sup> RVF virus continues as a threat due to its persistence in the environment. Although RVF infection in humans is usually self-limiting, it may develop severity including fatal hemorrhage,<sup>11</sup> leading to obstetric complications and neonatal infections. Definitive RVF diagnosis could be done through RT-PCR, LAMP, NGS, and antibody (IgM and IgG) detection through ELISA.<sup>12</sup> The pandemicity of RVFV and the unavailability of approved therapeutic and therapeutic measures are public health concerns.<sup>16</sup> State-of-the-art vaccine technology involving subunit protein, DNA,<sup>35,36</sup> virus replicon particle,<sup>37</sup> virus-like particle,<sup>38</sup> virus vectored,<sup>39</sup> and genetically modified live vaccines<sup>40</sup> could be tried. RVF illness causes major economic losses due to deaths and abortions among livestock.<sup>3</sup> High animal densities, insufficient sanitation services, and unstable environmental conditions contribute to the growth of vectors and viral transmission. Awareness campaigns on risk factors for RVF transmission and the preventative measures like vector management and protection from mosquito bites could reduce human infections and fatalities.<sup>4</sup>

## 12 | CONCLUSION

In light of the overwhelming healthcare situation the world has witnessed and is witnessing in the ongoing pandemic era, it is only prudent to be critical about a malady that is seemingly endemic and consider it as potentially pandemic until and unless it is epidemiologically verified and validated otherwise. To ensure a free and fair healthy world for one and all, preventive approaches with effective surveillance and monitoring system following the One Health model is extremely beneficial and recommended. As heavy rainfall, flood water runoff through rivers and canals helped in spreading the disease on previous instances, the epidemic response team needs to be managed through national level One Health model. Strengthening the surveillance, sanitation standards and policies is suggested. Environmental survivability of RVF-infected *Aedes* spp. eggs also needs assessment.

### AUTHOR CONTRIBUTIONS

**Ranjan K. Mohapatra:** Conceptualization; writing—original draft. **Lakshmi V. S. Kutikuppala:** Writing—original draft. **Venkataramana Kandi:** Writing—original draft. **Snehasish Mishra:** Writing—review

and editing. **Ali A. Rabaan:** Writing—review and editing. **Sharo Costa:** Writing—review and editing. **Zahraa Haleem Al-qaim:** Writing—review and editing. **Bijaya K. Padhi:** Writing—review and editing. **Ranjit Sah:** Conceptualization; supervision; writing—review and editing.

### ACKNOWLEDGMENTS

All the authors are thankful to their respective Institutions for their support.

### CONFLICT OF INTEREST STATEMENT

The authors declare no conflict of interest.

### TRANSPARENCY STATEMENT

The lead author Snehasish Mishra, Ranjit Sah affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

### DATA AVAILABILITY STATEMENT

All data included within the manuscript.

### ORCID

Ranjan K. Mohapatra  <http://orcid.org/0000-0001-7623-3343>

Bijaya K. Padhi  <http://orcid.org/0000-0002-2828-2375>

Ranjit Sah  <http://orcid.org/0000-0002-2695-8714>

### REFERENCES

1. Daubney R, Hudson JR, Garnham PC. Enzootic hepatitis or Rift Valley fever. An undescribed virus disease of sheep cattle and man from east Africa. *J Pathol Bacteriol.* 1931;34:545-579.
2. Caminade C, Ndione J, Diallo M, et al. Rift Valley fever outbreaks in Mauritania and related environmental conditions. *Int J Environ Res Public Health.* 2014;11:903-918. doi:10.3390/ijerph110100903
3. Kwaśnik M, Rożek W, Rola J. Rift Valley fever—a growing threat to humans and animals. *J Veter Res.* 2021;65(1):7-14.
4. World Health Organization. Rift Valley fever—Mauritania, 20 October 2022. Accessed October 28, 2022. <https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON417>
5. World Organization for Animal Health. Accessed October 30, 2022. <https://www.woah.org/en/disease/rift-valley-fever/>
6. Caminade C, Ndione JA, Kebe CMF, et al. Mapping Rift Valley fever and malaria risk over West Africa using climatic indicators. *Atmospheric Sci Letters.* 2011;12:96-103.
7. WHO. Workshop on prioritization of pathogens. *Blueprint for R&D Preparedness and Response to Public Health Emergencies due to Highly Infectious Pathogens.* World Health Organization; 2015.
8. Youssouf H, Subiros M, Denetiere G, et al. Rift Valley fever outbreak, Mayotte, France, 2018-2019. *Emerging Infect Dis.* 2020;26(4):769-772. doi:10.3201/eid2604.191147
9. Hartman A. Rift Valley fever. *Clin Lab Med.* 2017;37(2):285-301. doi:10.1016/j.cll.2017.01.004
10. Wichgers Schreur PJ, Vloet RPM, Kant J, et al. Reproducing the Rift Valley fever virus mosquito-lamb-mosquito transmission cycle. *Sci Rep.* 2021;11(1):1477. doi:10.1038/s41598-020-79267-1
11. McMillen CM, Hartman AL. Rift Valley fever: a threat to pregnant women hiding in plain sight. *J Virol.* 2021;95(9):e01394-19. doi:10.1128/JVI.01394-19

12. Petrova V, Kristiansen P, Norheim G, Yimer SA. Rift valley fever: diagnostic challenges and investment needs for vaccine development. *BMJ Glob Health*. 2020;5(8):e002694. doi:10.1136/bmjgh-2020-002694
13. Pawęska JT, Msimang V, Kgaladi J, Hellferscee O, Weyer J, Jansen van Vuren P. Rift Valley fever virus seroprevalence among humans, Northern KwaZulu-Natal Province, South Africa, 2018-2019. *Emerging Infect Dis*. 2021;27(12):3159-3162. doi:10.3201/eid2712.210643
14. Sanderson CE, Jori F, Moolla N, Paweska JT, Oumer N, Alexander KA. Silent circulation of Rift Valley fever in humans, Botswana, 2013-2014. *Emerging Infect Dis*. 2020;26(10):2453-2456. doi:10.3201/eid2610.191837
15. Ibrahim M, Schelling E, Zinsstag J, Hattendorf J, Andargie E, Tschopp R. Sero-prevalence of brucellosis, Q-fever and Rift Valley fever in humans and livestock in Somali Region, Ethiopia. *PLoS Neglected Trop Dis*. 2021;15(1):e0008100. doi:10.1371/journal.pntd.0008100
16. Wright D, Kortekaas J, Bowden TA, Warimwe GM. Rift Valley fever: biology and epidemiology. *J Gen Virol*. 2019;100(8):1187-1199. doi:10.1099/jgv.0.001296
17. Birungi D, Aceng FL, Bulage L, et al. Sporadic Rift Valley fever outbreaks in humans and animals in Uganda, October 2017-January 2018. *J Environ Public Health*. 2021;2021:1-8. doi:10.1155/2021/8881191
18. Ahmed A, Mahmoud I, Eldigail M, Elhassan R, Weaver S. The emergence of Rift Valley fever in Gedaref State urges the need for a cross-border one health strategy and enforcement of the international health regulations. *Pathogens*. 2021;10(7):885. doi:10.3390/pathogens10070885
19. Ndumu DB, Bakamutumaho B, Miller E, et al. Serological evidence of Rift Valley fever virus infection among domestic ruminant herds in Uganda. *BMC Vet Res*. 2021;17(1):157. doi:10.1186/s12917-021-02867-0
20. Gregor KM, Michaely LM, Gutjahr B, et al. Rift Valley fever virus detection in susceptible hosts with special emphasis in insects. *Sci Rep*. 2021;11(1):9822. doi:10.1038/s41598-021-89226-z
21. Ganaie SS, Schwarz MM, McMillen CM, et al. Lrp1 is a host entry factor for Rift Valley fever virus. *Cell*. 2021;184(20):5163-5178. doi:10.1016/j.cell.2021.09.001
22. Léger P, Lozach PY. Le virus de la fièvre de la vallée du Rift et son étonnante protéine NSs. *médecine/sciences*. 2021;37(6-7):601-608. doi:10.1051/medsci/2021090
23. Connors KA, Hartman AL. Advances in understanding neuropathogenesis of Rift Valley fever virus. *Annual Rev Virol*. 2022;9(1):437-450. doi:10.1146/annurev-virology-091919-065806
24. Quellec J, Salinas S, Simonin Y, Cêtre-Sossah C. Rift Valley fever virus infection: physiopathology and pathogenesis. *Virologie*. 2021;25(5):263-279. doi:10.1684/vir.2021.0919
25. Odendaal L, Davis AS, Venter EH. Insights into the pathogenesis of viral haemorrhagic fever based on virus tropism and tissue lesions of natural Rift Valley fever. *Viruses*. 2021;13(4):709. doi:10.3390/v13040709
26. Youssouf H, Subiros M, Dennetiere G, et al. Rift Valley fever outbreak, Mayotte, France, 2018-2019. *Emerging Infect Dis*. 2020;26(4):769-772. doi:10.3201/eid2604.191147
27. Ahmed A, Ali Y, Elduma A, et al. Unique outbreak of Rift Valley fever in Sudan, 2019. *Emerging Infect Dis*. 2020;26(12):3030-3033. doi:10.3201/eid2612.201599
28. El Mamy ABO, Baba MO, Barry Y, et al. Unexpected Rift Valley fever outbreak, Northern Mauritania. *Emerging Infect Dis*. 2011;17(10):1894-1896.
29. Barry Y, Elbara A, Bollahi MA, et al. Rift Valley fever, Mauritania, 2020: lessons from a one health approach. *One Health*. 2022;15:100413.
30. Nielsen SS, Alvarez J, Bicout DJ, et al. Rift Valley fever—epidemiological update and risk of introduction into Europe. *EFSA J*. 2020;18:6041. doi:10.2903/j.efsa.2020.6041
31. Stoek F, Barry Y, Ba A, et al. Mosquito survey in Mauritania: detection of Rift Valley fever virus and dengue virus and the determination of feeding patterns. *PLoS Neglected Trop Dis*. 2022;16(4):e0010203. doi:10.1371/journal.pntd.0010203
32. Randall R, Gibbs Jr. CJ, Aulisio CG, Binn LN, Harrison VR. The development of a formalin-killed Rift Valley fever virus vaccine for use in man. *J Immunol*. 1962;89:660-671.
33. Ikegami T, Makino S. Rift valley fever vaccines. *Vaccine*. 2009;27:D69-D72. doi:10.1016/j.vaccine.2009.07.046
34. Caplen H, Peters CJ, Bishop DHL. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. *J Gen Virol*. 1985;66:2271-2277. doi:10.1099/0022-1317-66-10-2271
35. Lagerqvist N, Näslund J, Lundkvist Å, Bouloy M, Ahlm C, Bucht G. Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley fever virus cDNA constructs. *Virol J*. 2009;6:6. doi:10.1186/1743-422x-6-6
36. Spik K, Shurtleff A, McElroy AK, Guttieri MC, Hooper JW, Schmaljohn C. Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. *Vaccine*. 2006;24:4657-4666. doi:10.1016/j.vaccine.2005.08.034
37. Oreshkova N, van Keulen L, Kant J, Moormann RJM, Kortekaas J. A single vaccination with an improved nonspreading Rift Valley fever virus vaccine provides sterile immunity in lambs. *PLoS One*. 2013;8:e77461. doi:10.1371/journal.pone.0077461
38. Mandell RB, Koukuntla R, Mogler LJK, et al. A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge. *Virology*. 2010;397:187-198. doi:10.1016/j.virol.2009.11.001
39. Warimwe GM, Gesharisha J, Carr BV, et al. Chimpanzee adenovirus vaccine provides multispecies protection against Rift Valley fever. *Sci Rep*. 2016;6:20617. doi:10.1038/srep20617
40. Bird BH, Albariño G, Hartman AL, Erickson BR, Ksiazek TG, Nichol ST. Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. *J Virol*. 2008;82:2681-2691. doi:10.1128/JVI.02501-07
41. Mohapatra RK, Kutikuppala SLV, Kudrat-E-Zahan M, et al. Resurging dengue cases among the Rohingya refugees in Bangladesh amid COVID-19 pandemic: a SouthEast Asia healthcare concern. *Ann Med Surg*. 2022;84:104962.

**How to cite this article:** Mohapatra RK, Kutikuppala LVS, Kandi V, et al. Rift valley fever (RVF) viral zoonotic disease steadily circulates in the Mauritanian animals and humans: a narrative review. *Health Sci Rep*. 2023;6:e1384. doi:10.1002/hsr2.1384